Compare NTGR & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTGR | RCKT |
|---|---|---|
| Founded | 1996 | 1999 |
| Country | United States | United States |
| Employees | 784 | 202 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 606.4M | 534.2M |
| IPO Year | 2000 | N/A |
| Metric | NTGR | RCKT |
|---|---|---|
| Price | $21.57 | $4.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $39.00 | $29.65 |
| AVG Volume (30 Days) | 371.4K | ★ 2.8M |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.64 | $97.68 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.75 | $2.19 |
| 52 Week High | $36.86 | $8.80 |
| Indicator | NTGR | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 53.18 | 56.97 |
| Support Level | $21.30 | $2.99 |
| Resistance Level | $21.88 | $5.34 |
| Average True Range (ATR) | 0.69 | 0.38 |
| MACD | 0.15 | 0.02 |
| Stochastic Oscillator | 80.73 | 47.90 |
Netgear Inc provider of networking technologies for businesses, homes, and service providers. It delivers a wide range of intelligent solutions designed to unleash the full potential of connectivity. The group has two segments: Enterprise and Consumer which offers reliable, easy-to-use, high-performance networking solutions, including switches, routers, access points, software, and AV over IP technologies, tailored to meet the diverse needs of organizations of all sizes. The Home Networking and Mobile offers connectivity, powerful performance, and enhanced security features right out of the box, designed to help keep families safe online, and Others. It conduct business across three geographic territories: Americas; Europe, Middle East and Africa; and Asia Pacific.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.